Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX)

Historical Holders from Q1 2022 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
AMLX on Nasdaq
Shares outstanding
110,784,314
Price per share
$12.08
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
109,720,694
Holdings value
$1,491,122,082
% of all portfolios
0.01%
Share change
+28,023,346
Value change
+$396,029,872
Average buys %
+0%
Average sells %
-0%
Number of holders
168
Price from insider filings
$11.11
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 11% $154,666,182 11,379,207 FMR LLC 30 Sep 2025
PERCEPTIVE ADVISORS LLC 8.2% -6.7% $121,662,640 +$14,650,251 8,952,365 +14% Perceptive Advisors LLC 30 Sep 2025
Adage Capital Management, L.P. 6.4% -35% $92,640,693 -$26,951,307 6,816,828 -23% Adage Capital Management, L.P. 30 Sep 2025
Commodore Capital LP 5.1% $89,213,500 5,650,000 Commodore Capital LP 10 Nov 2025
VANGUARD GROUP INC 4.9% -2% $71,672,372 +$10,542,372 5,273,750 +17% The Vanguard Group 30 Sep 2025
BlackRock, Inc. 5.5% $31,547,244 4,917,501 BlackRock, Inc. 30 Jun 2025
Point72 Asset Management, L.P. 2.6% -54% $38,074,233 -$26,039,432 2,801,636 -41% Point72 Asset Management, L.P. 30 Sep 2025
Panacea Innovation Ltd 2.6% $11,792,000 2,200,000 Panacea Venture Healthcare Fund II, L.P. 31 Dec 2024
As of 30 Sep 2025, Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) has 168 institutional shareholders filing 13F forms. They hold 109,720,694 shares of 110,784,314 outstanding shares (99%) .

Top 25 institutional shareholders own 79% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 10% 11,379,207 +273% 0.01% $154,643,424
PERCEPTIVE ADVISORS LLC 8.1% 8,952,365 +13% 3.6% $121,662,640
BlackRock, Inc. 6.4% 7,140,692 +30% 0% $97,042,005
ADAGE CAPITAL PARTNERS GP, L.L.C. 6.2% 6,816,828 -23% 0.15% $92,640,693
TCG Crossover Management, LLC 5.6% 6,243,812 +5% 4.2% $84,853,405
VANGUARD GROUP INC 4.8% 5,273,750 +17% 0% $71,670,263
Saturn V Capital Management LP 4.2% 4,604,878 +41% 14% $62,580,292
Commodore Capital LP 3.7% 4,075,478 2.7% $55,385,746
First Light Asset Management, LLC 3% 3,355,882 4.3% $45,606,436
Point72 Asset Management, L.P. 2.5% 2,790,066 -38% 0.08% $37,916,998
JANUS HENDERSON GROUP PLC 2.3% 2,536,233 0.02% $34,454,725
Driehaus Capital Management LLC 2.2% 2,420,767 +91% 0.24% $32,898,224
Almitas Capital LLC 1.9% 2,122,597 0% 6.6% $28,846,093
GOLDMAN SACHS GROUP INC 1.8% 2,010,633 +55% 0% $27,324,503
MORGAN STANLEY 1.8% 1,950,301 +301% 0% $26,504,591
Paradigm Biocapital Advisors LP 1.7% 1,900,000 0.76% $25,821,000
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,812,039 +7.1% 0% $24,631,001
683 Capital Management, LLC 1.6% 1,760,000 -19% 2.2% $23,918,400
GREAT POINT PARTNERS LLC 1.5% 1,700,000 -15% 9.6% $23,103,000
STATE STREET CORP 1.5% 1,621,260 +61% 0% $22,032,923
EVENTIDE ASSET MANAGEMENT, LLC 1.4% 1,512,500 0.34% $20,554,948
Balyasny Asset Management L.P. 1.3% 1,476,302 0.04% $20,062,944
Logos Global Management LP 1.3% 1,450,000 1.9% $19,705,500
UBS Group AG 1.3% 1,404,471 +12% 0% $19,086,761
DEUTSCHE BANK AG\ 1.2% 1,365,521 +121% 0.01% $18,557,430

Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 21,353 $258,124 +$109,788 $12.08 4
2025 Q3 109,720,694 $1,491,122,082 +$396,029,872 $13.59 168
2025 Q2 81,690,006 $523,632,250 +$57,316,535 $6.41 131
2025 Q1 73,877,500 $261,528,744 +$85,099,354 $3.54 134
2024 Q4 49,784,011 $188,180,501 +$19,458,443 $3.78 120
2024 Q3 43,406,257 $140,608,833 +$5,128,506 $3.24 107
2024 Q2 43,632,024 $82,904,189 -$16,885,307 $1.90 115
2024 Q1 49,485,594 $140,539,742 -$234,955,037 $2.84 138
2023 Q4 60,281,638 $887,348,868 -$11,902,243 $14.72 177
2023 Q3 58,927,724 $1,078,966,869 +$84,065,478 $18.31 168
2023 Q2 54,545,075 $1,176,653,052 +$56,163,167 $21.57 153
2023 Q1 51,372,917 $1,507,231,117 +$73,671,274 $29.34 145
2022 Q4 48,572,530 $1,794,757,212 +$422,522,242 $36.95 131
2022 Q3 36,858,311 $1,037,561,470 +$315,174,073 $28.15 90
2022 Q2 26,621,859 $512,910,346 +$65,322,870 $19.26 74
2022 Q1 23,420,880 $299,935,403 +$299,912,422 $12.85 72